Comment
doi: 10.1200/JCO.19.01179.
Epub 2019 Sep 25.
Treatment of Ovarian Cancer With Intraperitoneal Platinum: Heating Up the Debate
Affiliations
- PMID: 31553679
- DOI: 10.1200/JCO.19.01179
Item in Clipboard
Comment
Treatment of Ovarian Cancer With Intraperitoneal Platinum: Heating Up the Debate
J Clin Oncol.
.
No abstract available
Comment in
-
Reply to F. Tomao et al and E.A. De Jaeghere et al.J Clin Oncol. 2019 Nov 20;37(33):3170. doi: 10.1200/JCO.19.02091. Epub 2019 Sep 25. J Clin Oncol. 2019. PMID: 31553678 No abstract available.
Comment on
-
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.J Clin Oncol. 2019 Jun 1;37(16):1380-1390. doi: 10.1200/JCO.18.01568. Epub 2019 Apr 19. J Clin Oncol. 2019. PMID: 31002578 Free PMC article. Clinical Trial.
Similar articles
-
Platinum-sensitive ovarian cancer: liminal advances.Lancet Oncol. 2020 May;21(5):614-615. doi: 10.1016/S1470-2045(20)30178-9. Epub 2020 Apr 16. Lancet Oncol. 2020. PMID: 32305100 No abstract available.
-
Bevacizumab improves overall survival in platinum refractory ovarian cancer patients: A retrospective study.Taiwan J Obstet Gynecol. 2018 Dec;57(6):819-824. doi: 10.1016/j.tjog.2018.10.009. Taiwan J Obstet Gynecol. 2018. PMID: 30545534
-
Treatment of recurrent ovarian cancer.Ann Oncol. 2017 Nov 1;28(suppl_8):viii51-viii56. doi: 10.1093/annonc/mdx441. Ann Oncol. 2017. PMID: 29232464 Review.
-
Impact of Adding Bevacizumab to Paclitaxel + Carboplatin for Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Propensity Score Matching Analysis.Tokai J Exp Clin Med. 2018 Sep 20;43(3):85-89. Tokai J Exp Clin Med. 2018. PMID: 30191541
-
Frontline treatment of epithelial ovarian cancer.Asia Pac J Clin Oncol. 2015 Dec;11 Suppl 6:1-16. doi: 10.1111/ajco.12449. Asia Pac J Clin Oncol. 2015. PMID: 26669253 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
